Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Core Insights - Neuphoria Therapeutics Inc. has achieved the Last Patient Last Visit (LPLV) milestone in the AFFIRM-1 Phase 3 trial for BNC-210, targeting social anxiety disorder (SAD), with topline data expected in early Q4 2025 [1][9] - The company's cash runway has been extended through fiscal Q2 2027, with cash and cash equivalents reported at $14.2 million as of June 30, 2025 [4][6] Clinical Program Highlights - BNC-210 is a selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, under development for SAD and PTSD, and has received FDA Fast Track designation [7][8] - The drug has shown rapid-onset and meaningful anti-anxiety effects in clinical trials without sedation or cognitive impairment [7][10] Financial Results - Research and development expenses decreased to $9.0 million for the fiscal year ended June 30, 2025, from $9.4 million in the previous year [5] - General and administrative expenses also decreased to $7.8 million from $8.5 million year-over-year [6] - The net loss for the year was $0.4 million, significantly reduced from a net loss of $15.5 million in the prior year [6][14] Future Plans - Neuphoria plans to initiate the SYMPHONY Phase 2b/3 trial for PTSD in the first half of 2026 [9] - The company is advancing two positive allosteric modulator candidates in partnership with Merck & Co., Inc., currently in a Phase 2 trial for Alzheimer's disease [9][10]